SOTIO has been building a diverse biotechnology portfolio through own R&D, partnering and investments since 2010. It’s focusing on immuno-oncology and developing innovative methods of the treatment of cancer. SOTIO is conducting multiple Phase I to III clinical trials and projects in preclinical stage. The company has facilities in Europe, the US, China and Russia.
Sotio
